Revolution Medicines/RVMD

$37.95

-0.47%
-
1D1W1MYTD1YMAX

About Revolution Medicines

Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. Its RAS Companion Inhibitors are designed primarily for combination treatment strategies centered on its RAS(ON) Inhibitors. The Company’s RAS(ON) Inhibitors RMC-6236 RMC-6291 and RMC-9805 are in clinical development. RMC-6236, its RASMULTI(ON) inhibitor, is designed as a potent, oral, RAS-selective tri-complex inhibitor of multiple RAS(ON) variants, including cancer drivers.

Ticker

RVMD

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Mark Goldsmith

Employees

411

Headquarters

Redwood city, United States

RVMD Metrics

BasicAdvanced
$6.3B
Market cap
-
P/E ratio
-$3.76
EPS
1.45
Beta
-
Dividend rate
$6.3B
1.44652
$40.63
$15.44
1.5M
18.45
-32.48%
-36.17%
-34.18%
1,377.776
3.644
3.805
-86.89%
-23.58%
-35.41%

What the Analysts think about RVMD

Analyst Ratings

Majority rating from 13 analysts.
Buy

Price Targets

Average projection from 11 analysts.
20.03% upside
High $50.00
Low $40.00
$37.95
Current price
$45.55
Average price target

RVMD Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
-100%
Net income
-$116M
-28.17%
Profit margin
0%
-100%

RVMD Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 6.18%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.92
-$0.99
-$1.14
-$0.70
-
Expected
-$0.82
-$1.01
-$0.88
-$0.75
-$0.75
Surprise
11.68%
-1.29%
29.24%
-6.18%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Revolution Medicines stock?

Revolution Medicines (RVMD) has a market cap of $6.3B as of May 25, 2024.

What is the P/E ratio for Revolution Medicines stock?

The price to earnings (P/E) ratio for Revolution Medicines (RVMD) stock is 0 as of May 25, 2024.

Does Revolution Medicines stock pay dividends?

No, Revolution Medicines (RVMD) stock does not pay dividends to its shareholders as of May 25, 2024.

When is the next Revolution Medicines dividend payment date?

Revolution Medicines (RVMD) stock does not pay dividends to its shareholders.

What is the beta indicator for Revolution Medicines?

Revolution Medicines (RVMD) has a beta rating of 1.45. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Revolution Medicines stock price target?

The target price for Revolution Medicines (RVMD) stock is $45.55, which is 20.03% above the current price of $37.95. This is an average based on projections from 11 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Revolution Medicines stock

Buy or sell Revolution Medicines stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing